Pyrimethamine drug interactions: Difference between revisions
(Created page with "__NOTOC__ {{Pyrimethamine}} {{CMG}}; {{AE}} {{chetan}} ==Drug Interactions== Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other anti...") |
|||
| Line 4: | Line 4: | ||
==Drug Interactions== | ==Drug Interactions== | ||
Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. However, the concomitant use of other antifolic drugs or agents associated with myelosuppression including sulfonamides or trimethoprim-sulfamethoxazole combinations, proguanil, zidovudine, or cytostatic agents (e.g., methotrexate), while the patient is receiving pyrimethamine, may increase the risk of bone marrow suppression. If signs of folate deficiency develop, pyrimethamine should be discontinued. Folinic acid (leucovorin) should be administered until normal hematopoiesis is restored (see WARNINGS). Mild hepatotoxicity has been reported in some patients when lorazepam and pyrimethamine were administered concomitantly.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = DARAPRIM (PYRIMETHAMINE) TABLET [AMEDRA PHARMACEUTICALS LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e4d5027-7939-480f-ae19-82e764d9fa97#nlm34089-3 | publisher = | date = | accessdate = }}</ref> | Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. However, the concomitant use of other antifolic drugs or agents associated with [[myelosuppression]] including sulfonamides or [[trimethoprim-sulfamethoxazole]] combinations, [[proguanil]], [[zidovudine]], or [[cytostatic agents]] (e.g.,[[ methotrexate]]), while the patient is receiving pyrimethamine, may increase the risk of bone marrow suppression. If signs of folate deficiency develop, pyrimethamine should be discontinued. Folinic acid ([[leucovorin]]) should be administered until normal hematopoiesis is restored (see WARNINGS). Mild hepatotoxicity has been reported in some patients when lorazepam and pyrimethamine were administered concomitantly.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = DARAPRIM (PYRIMETHAMINE) TABLET [AMEDRA PHARMACEUTICALS LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e4d5027-7939-480f-ae19-82e764d9fa97#nlm34089-3 | publisher = | date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
Revision as of 21:40, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Drug Interactions
Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. However, the concomitant use of other antifolic drugs or agents associated with myelosuppression including sulfonamides or trimethoprim-sulfamethoxazole combinations, proguanil, zidovudine, or cytostatic agents (e.g.,methotrexate), while the patient is receiving pyrimethamine, may increase the risk of bone marrow suppression. If signs of folate deficiency develop, pyrimethamine should be discontinued. Folinic acid (leucovorin) should be administered until normal hematopoiesis is restored (see WARNINGS). Mild hepatotoxicity has been reported in some patients when lorazepam and pyrimethamine were administered concomitantly.[1]
References
Adapted from the FDA Package Insert.